Breaking Down the Cost-Effectiveness of Quadruple Therapy for Heart Failure with Reduced Ejection Fraction

A cost-effectiveness analysis examines quadruple therapy's value in treating heart failure with reduced ejection fraction. The addition of SGLT2 inhibitors and angiotensin receptor-neprilysin inhibitor is evaluated for its impact on patient outcomes and affordability.